Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Director | February 04, 2025 | February 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seres Therapeutics, Inc.
Report date February 04, 2025 · Filed February 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.81 · Expires 2035-02-03 | Direct | 120,000 |
Reported balance
After 2025-02-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-04 · Grant · Acquired 120,000 · Balance 120,000 F1: The option will vest in four substantially equal installments on each anniversary of February 4, 2025 or in full immediately prior to the occurrence of a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in four substantially equal installments on each anniversary of February 4, 2025 or in full immediately prior to the occurrence of a change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2025 Filed Feb 6, 2025 08:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0000950170-25-015020 · ownership.xml · derivative · entry 1 Woerle Hans-Juergen · CIK 0002046489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The option will vest in four substantially equal installments on each anniversary of February 4, 2025 or in full immediately prior to the occurrence of a change in control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.